This randomized, single-blind, multicentre, multinational study compared recombinant
human FSH (rhFSH,
Gonal-F) with highly purified
urinary human FSH (uhFSH,
Metrodin HP) in women undergoing ovarian stimulation for IVF/intracytoplasmic sperm injection (ICSI). Following desensitization in a long gonadotrophin-releasing
hormone (
GnRH) agonist protocol, patients received s.c.
Gonal-F or
Metrodin HP, at a fixed dose of 150 IU, until there was adequate follicular development. Of 496 women randomized, 232 and 231 in the
Gonal-F and
Metrodin HP groups respectively received human chorionic gonadotrophin (HCG). The duration of FSH treatment was significantly shorter with
Gonal-F than with
Metrodin HP (11.6 +/- 1.9 days versus 12. 4 +/- 2.7 days; P < 0.0001) and significantly fewer ampoules were required (mean 22.6 +/- 5.0 versus 24.3 +/- 5.1, P < 0.0002). There were, however, significantly more follicles > or =10 mm in diameter with
Gonal-F (15.6 +/- 8.2 versus 13.6 +/- 7.1, P < 0.01) and oocytes retrieved (13.1 +/- 7.7 versus 11.4 +/- 7.6, P < 0.002). Although no statistical difference in pregnancy rate was recorded, patients receiving
Gonal-F had a higher pregnancy rate per cycle than patients given
Metrodin HP (25.1 versus 20.1%). Moderate to severe
ovarian hyperstimulation syndrome occurred in 2.8 and 1.2% of
Gonal-F and
Metrodin HP patients respectively (not significant). In conclusion, FSH stimulation in combination with a long
GnRH agonist protocol is effective in inducing multiple follicular development and embryos with a high implantation potential. However,
Gonal-F is clearly more effective than
Metrodin HP in inducing multifollicular development.